Curcuma Extract Enhances Hepatoprotective Action of Silymarin in Experimental Liver Damage Models

실리마린의 간보호 작용에 미치는 쿠쿠마 추출물의 영향

  • 이기명 (아주대학교 의과대학 소화기내과) ;
  • 함기백 (아주대학교 의과대학 소화기내과) ;
  • 조성원 (아주대학교 의과대학 소화기내과) ;
  • 오태영 (동아제약(주) 연구소) ;
  • 최설민 (동아제약(주) 연구소) ;
  • 김정훈 (동아제약(주) 연구소) ;
  • 안병옥 (동아제약(주) 연구소) ;
  • 권종원 (동아제약(주) 연구소) ;
  • 김원배 (동아제약(주) 연구소)
  • Published : 2002.03.01


Silymarin and curcumin have been used for supportive treatment of liver disease of difffrent etiology due to their hepatoprotective activities. The present study was carried out to investigate the hepatoprotective efffcts of silymarin and/or curcuma extract against hepatotoxins induced liver injury. To investigate hepatoprotective effects, the silymarin and/or curcuma extract were pre-treated orally to experimental animals. And thereafter a single dose of hepatotoxin, carbon tetrachloride ($CCl_4$) and acetaminophen were administered through oral or intraperitoneal route, respectively. Chronic liver damage was induced by subcutaneous injection of $CCl_4$ for 3 weeks (2 times/week). Hepatoprotective and therapeutic effects were monitored by estimating serurn ALT and AST levels and by measuring hepatic glutathione (GSH) and malondialdehyde (MDA)levels. Collagen type 1 was detected with irnrnunostaining to assess fibrosis. The results showed that the mix-ture of silymarin and curcuma extract significantly reduced serum biochemistry levels and MDA levels com-pared with those of control group in both acute and chronic animal models. In antifibrotic effect, the relative hepatic collagen content was significantly decreased by silymarin and/or curcuma extract treatment. It was concluded that the complex of silymarin and curcuma extract have a both hepatoprotective and therapeutic effect synergically in rat liver injury induced by heptotoxins.



  1. Chuang, S. E., Kuo, M. L., Hsu, C. H., Chen, C. R., Lin, J. K., Lai, G. M., Hsieh, C. Y. and Cbeng, A. L. (2000). Curcumin-containing diet inhibits diethylmtrosamine induced murine hepatocarcinogenesis. Carcinogenesis 21, 331-335
  2. Dehmlow, C., Erhard, J. and de Groot, H. (1996). Inhibition of Kupffer cell functions as an explanation for the bepatoprotective properties of silibinin. Hepatology 23, 749-754
  3. Ferenci, P., Dragosics, B., Diltrich, H., Frank, H., Benda, L., Lochs, H., Meryn, S., Base, W. and Schneider, B. (1989) Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.J. Hepatol. 9, 105-113
  4. Halim, A. B., el-Ahmady, 0., Hassab-Allah, S., Abdel-Galil, F., Hafez, Y. and Darwish, A. (1997). A Biochemical effect of antioxidatits on lipids and liver function in experi-mentally-induced liver damage. Ann. Clin. Biochem. 34, 656-663
  5. Ishii, K., Matama, S., Shibata, H., Okabe, H., Okudaira, M., Nagata, H. and Tsuchiya, M. (1984). Mici-ocirculatory responses to estradiol benzoate in chronic liver damage induced by carbon tetrachlohde in the rat. Gastroenterol. Jpn. 19, 419-423
  6. Janbaz, K. H. and Gilani, A. H. (1995). Evaluation of the protective potential of Artemisia maritima extract on acetamninophen- and CCL-induced liver damage. J. Ethnopharmacol. 41, 43-47
  7. Jia, J. D., Bauer, M., Cho, J. J., Ruehl, M., Milani, S., Boigk, G- Riecken, E. 0. and Schuppan, D. (2001). Antifibrotic effect of silymarm in rat secondary biliary fibrosis is mediated by downregulation of procollagen alphal (1) and TIMP-1.J. Hepatol. 35, 392-398
  8. Kawamori, T., Lubet, R., Steele, V. E., Kellofr, G. J., Kaskey, R. B., Rao, C. V. and Reddy, B. S. (1999). Chemopreventive effect of curcumin, a naturally occurring anti inflammatory agcnt, during the promotion/progression stagcs of colon cancer. Cancer Res. 59, 597-601
  9. Lin, J. K., Pan, M. H. and Lin-Shiau, S. Y. (2000). Recent studies on the biofunctions and biotransformatioiis of curcumin. Biofactors 13, 153-158
  10. Ramsewak, R. S., DeWitt, D. L. and Nair, M. G. (2000). Cytotoxicity, anlioxidant and anti-inflammatory activities of curcumins l-III from Curcuma longa. Phytomedicine 7, 303-308
  11. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J. (1951) Protein measurement with the Folin phenol reagent. J. BioI. Chem. 193, 265-275
  12. Mascher H., Kikuta, C. and Weyhenmeyer, R. (1993). Diasteromeric separation of free and conjugated silibinin in plasma by re ersed phase HPLC after specific extraction. J. Liquid Chromatogr. 16, 2777-2789
  13. Miguez, M. P., Anundi, I., Sainz-Pardo, L. A. and Lindros, K. 0. (1994). Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem. Biol. Interact. 91, 51-63
  14. Ohkawa, H., Ohishi, N. and Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95, 351-358
  15. Park, E. J., Jeon, C. H., Ko, G., Kim, J. and Sohn, D. H. (2000). Protective effect of curcumin in rat liver injury induced by carbon tetrachloride. J. Pharm. Pharmacol. 52, 437-440
  16. Piper, J. T., Singhal, S. S., Salameh, M. S., Torman, R. T., Awasthi, Y. C. and Awasthi, S. (1998). Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver. Int. J. Biochem. Cell Biol. 30, 445-456
  17. Punithavathi, D., Venkatesan, N. and Babu, M. (2000). Curcumin inhibition of bleomycin-induced pulmonaiy fibrosis in rats. Br. J. PharmacoI. 131, 169-172
  18. Salmi, H. A. and Sarna, S. (1982). Effect of silymain on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand. J. Gastro-enterol. 17, 517-521
  19. Savio, D., Harrasser, P. C. and Basso, G. (1998). Softgel capsule technology as an enhancer device for the absorption of natural principles in humans. A bioavailability cross-over randomised study on silybin. Arzneimittelforschung 48, 1104-1106
  20. Schandalik, R., Gatti, G. and Perucca. E. (1992). Pharma-cokinetics of silybin in bile following administration of silipide aiid silymarin in cholecystectomy patients. Arz-neimittelforschung 42, 964-968
  21. Skottova, N. and Krecman, V. (1998). Silymarin as a potential hypocholesterolaemic drug. PhysioI. Res. 47, 1-7